BioCardia’s (BCDA) “Buy” Rating Reiterated at HC Wainwright

BioCardia (NASDAQ:BCDA)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $25.00 price objective on the stock.

Several other analysts have also recently issued reports on the stock. Zacks Research upgraded shares of BioCardia from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of BioCardia from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $25.00.

BioCardia Stock Down 1.0%

BCDA traded down $0.01 during trading hours on Monday, hitting $1.00. The stock had a trading volume of 126,842 shares, compared to its average volume of 1,272,767. The stock has a market cap of $15.14 million, a PE ratio of -1.56 and a beta of 0.48. The company’s fifty day simple moving average is $0.96 and its 200 day simple moving average is $1.07. BioCardia has a 1 year low of $0.75 and a 1 year high of $2.29.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05. As a group, equities analysts expect that BioCardia will post -0.71 EPS for the current year.

Insider Buying and Selling

In other BioCardia news, Director Simon H. Stertzer acquired 39,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were acquired at an average price of $1.00 per share, with a total value of $39,000.00. Following the completion of the purchase, the director directly owned 166,338 shares of the company’s stock, valued at approximately $166,338. The trade was a 30.63% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have bought a total of 140,700 shares of company stock worth $131,966 over the last 90 days. Insiders own 17.40% of the company’s stock.

Institutional Investors Weigh In On BioCardia

Several hedge funds have recently added to or reduced their stakes in BCDA. Geode Capital Management LLC grew its position in BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after purchasing an additional 27,263 shares during the last quarter. DRW Securities LLC bought a new stake in BioCardia in the 4th quarter worth about $72,000. Finally, Cetera Investment Advisers purchased a new position in BioCardia in the 2nd quarter worth about $40,000. 20.57% of the stock is owned by institutional investors.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.